Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

about

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Item

http://www.wikidata.org/entity/Q49953686

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Real-life experience of ceriti ...... all cell lung cancer patients.

@en

Real-life experience of ceriti ...... all cell lung cancer patients.

@nl

type

Item

label

Real-life experience of ceriti ...... all cell lung cancer patients.

@en

Real-life experience of ceriti ...... all cell lung cancer patients.

@nl

prefLabel

Real-life experience of ceriti ...... all cell lung cancer patients.

@en

Real-life experience of ceriti ...... all cell lung cancer patients.

@nl

P1476

Real-life experience of ceriti ...... mall cell lung cancer patients

@en

P2093

Alexandru Buturuga

http://www.w3.org/2001/XMLSchema#string

Benjamin Besse

http://www.w3.org/2001/XMLSchema#string

Bertrand Mennecier

http://www.w3.org/2001/XMLSchema#string

Eric Dansin

http://www.w3.org/2001/XMLSchema#string

Fabrice Barlesi

http://www.w3.org/2001/XMLSchema#string

Gilles Robinet

http://www.w3.org/2001/XMLSchema#string

Hervé Lena

http://www.w3.org/2001/XMLSchema#string

Jacques Cadranel

http://www.w3.org/2001/XMLSchema#string

Julien Mazieres

http://www.w3.org/2001/XMLSchema#string

Khemaies Slimane

http://www.w3.org/2001/XMLSchema#string

P2860

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

P31

scholarly article

P356

10.1183/23120541.00058-2017

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Clarisse Audigier-Valette

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29450203

http://www.w3.org/2001/XMLSchema#string

P921

ceritinib

crizotinib

P932

5810621

http://www.w3.org/2001/XMLSchema#string